Last reviewed · How we verify

NCT04295928: GREPH

Establishment of a Personalized Pharmaceutical Plan in Renal or Hepatic Transplant Patients

Status unknown NA Last updated 3 November 2022
What this trial tests

NA trial testing PPP in Personalized Pharmaceutical Plan After Transpantation in 1,716 participants. Status unknown.

Timeline
12 October 2020
Primary endpoint
11 September 2022
11 September 2025

Quick facts

Lead sponsorUniversity Hospital, Tours
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposesupportive care
Enrollment1,716
Start date12 October 2020
Primary completion11 September 2022
Estimated completion11 September 2025
Sites12 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Tours

Who can join

18 and older, any sex, with Personalized Pharmaceutical Plan After Transpantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the study is to evaluate the impact of the Personalized Pharmaceutical Plan on the therapeutic adherence to immunosuppressive treatments one year after liver or kidney transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Implementing a personalized pharmaceutical plan in kidney or liver transplant patients: study protocol for a stepped-wedge cluster randomized trial (GRePH).
    Pourrat X, Berthy E, Dupuis A, Barbier L, et al · · 2021 · cited 2× · PMID 34749777 · DOI 10.1186/s13063-021-05749-w

Verify or expand the search:

Other trials of PPP

Trials testing the same drug.

Other University Hospital, Tours trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04295928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing